Roche’s Ale­cen­sa trumps Pfiz­er’s Xalko­ri in front­line ALK+ lung can­cer

A lit­tle more than a year af­ter Roche won an ac­cel­er­at­ed ap­proval for Ale­cen­sa as a new drug for treat­ment-re­sis­tant ALK-pos­i­tive non-small cell lung can­cer, the can­cer drug pow­er­house has trumped Pfiz­er’s Xalko­ri as a front­line ther­a­py, beat­ing out their ri­val on pro­gres­sion-free sur­vival.

Roche won the first ap­proval for Ale­cen­sa based on ev­i­dence of tu­mor shrink­age in Phase II. Re­searchers al­so high­light­ed a 61% re­sponse rate in pa­tients with brain or CNS metas­tases to help dis­tin­guish the new ar­rival.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.